“Biological drugs based on monoclonal antibodies (mAbs) have emerged as a preferred option for treating various cancer types, especially for blood cancer (leukemia). Rising incidence of various cancer conditions, growing popularity of advance therapies (biological and targeted drug therapies), patents expiration of leading drugs along with commercialization of biosimilars are the few factors driving the growth of global oncology drugs market. However, high cost involved in new drug development coupled with threat of failure and adverse effects associated with cancer drugs therapies would restrain the growth of the market. Commercialization of advanced therapeutics such as targeted and immunotherapies would reduce the negative influence of restraints and fuel the market growth.
The global oncology drugs market is expected to reach at $111.9 billion by 2020. Patent expiration of key cancer drugs such as Herceptin, Erbitux, Rituxan and Avastin, is expected to boost the growth of cancer biosimilars market by 2020. Going further, the biological therapies are expected to dominate the market by 2020, due to their high efficacy, target specific action and less toxicity. Blood cancer drugs market was the largest revenue generating segment in 2013 owing to the high cost of drugs (immunotherapies) used for the treatment of blood cancer.
Geographically, North America, dominates the market followed by Europe. North America accounted for about ~38% share in the overall oncology drugs market in 2013 owing to the heavy investments by multinational companies in research and development of cancer drugs, particularly immune therapeutics, favorable reimbursement policies, and high adoption rate of immunotherapies. On the other hand, Asia-Pacific market would grow at the promising CAGR of 8.7% during the forecast period. Such high growth rate is majorly due to increasing awareness towards advanced therapies namely immunotherapies and increase in per capita healthcare spending.
Key companies profiled in the report are Roche diagnostics, Novartis AG, Celgene Corporation, AstraZeneca, Johnson & Johnson, Merck & Co., Eli Lilly & Co. and GlaxoSmithKline. Companies operating in the cancer drugs market focus on several strategies such as collaboration, approval and acquisition.KEY BENEFITS
The report provides the quantitative analysis of the current market and estimations through 2013-2020 that assists in identifying the prevailing market opportunities to capitalize on
The report helps in understanding the strategies adopted by various companies for gaining market share in the cancer drugs market
The report provides comprehensive analysis of factors that drive and restrict the growth of the cancer drugs market
Market conditions of cancer drugs market across all geographic regions are comprehensively analyzed
Competitive intelligence (of leading manufacturers) helps in understanding the competitive scenario across the geographies
SWOT analysis of the key market players is provided to illustrate the business strategies adopted by the companies
MARKET SEGMENTATION
The cancer drugs market is segmented by the therapeutic modalities, cancer types and geography.
MARKET BY THERAPEUTIC MODALITIES
Chemotherapy
Targeted Therapy
Immunotherapy (Biologic Therapy)
Hormonal Therapy
Others
MARKET BY CANCER TYPES
Blood Cancer
Breast Cancer
Gastrointestinal Cancer
Prostate Cancer
Respiratory/Lung Cancer
Skin Cancer
Other Cancers
MARKET BY GEOGRAPHY
North America
United States
Canada
Mexico
Europe
Germany
France
United Kingdom
Others
Asia-Pacific
India
China
Japan
Australia
Others
LAMEA
GCC (Gulf Corporation Council)
Others”
“CHAPTER 1 INTRODUCTION
1.1 Report description
1.2 Key benefits
1.3 Key market segment
1.4 Research methodology
1.4.1 Secondary research
1.4.2 Primary research
1.4.3 Analyst tools and models
CHAPTER 2 EXECUTIVE SUMMARY
2.1 Market beyond what to expect by 2025
2.1.1 Moderate growth scenario
2.1.2 Rapid growth scenario
2.1.3 Diminishing growth scenario
CHAPTER 3 MARKET OVERVIEW
3.1 Market definition and scope
3.2 Development of novel immuno-oncology drug products
3.3 Key findings
3.3.1 Top Factors impacting oncology drugs market
3.3.2 Top investment pockets of oncology drugs market
3.3.3 Top winning strategies of oncology drugs market
3.4 Porter’s five forces analysis
3.4.1 Bargaining power of buyers (low)
3.4.2 Bargaining power of suppliers (moderate)
3.4.3 Threat of new entrants (Low)
3.4.4 Threat of substitutes (moderate)
3.4.5 Intense competitive rivalry
3.5 Value chain analysis
3.5.1 Primary activities
3.5.2 Support activities
3.6 Government regulations and reimbursement
3.6.1 Regulations in United States
3.6.2 Regulations in Europe
3.6.3 Regulations in Asia-Pacific
3.6.4 Reimbursement scenario
3.7 Patent analysis
3.7.1 Patent Analysis by type of patents
3.7.2 Patent analysis by geography
3.8 Market share analysis, 2013
3.9 Clinical trials for oncology drugs
3.10 Market dynamics
3.10.1 Drivers
3.10.1.1 Rising incidence and prevalence of various cancer types
3.10.1.2 Growing importance of biological and targeted drug therapies
3.10.1.3 Expiration of key patents and biosimilars impact
3.10.1.4 Acquisitions and collaborations – bolt-on strategies driving the market growth
3.10.2 Restraints
3.10.2.1 High cost of drug development and threat of failure
3.10.2.2 Adverse effects of anti-cancer drug therapy
3.10.3 Opportunities
3.10.3.1 Advancement of anti-cancer drugs research
3.10.3.2 Personalized medicine approach
CHAPTER 4 GLOBAL ONCOLOGY/CANCER DRUGS MARKET BY THERAPEUTIC MODALITIES
4.1 Chemotherapy
4.1.1 Key market trends
4.1.2 Key growth factors and opportunities
4.1.3 Market size and forecast
4.2 Targeted therapy
4.2.1 Key market trends
4.2.2 Key growth factors and opportunities
4.2.3 Market size and forecast
4.3 Immunotherapy (biologics therapy)
4.3.1 Key market trends
4.3.2 Key growth factors and opportunities
4.3.3 Market size and forecast
4.4 Hormonal therapy
4.4.1 Key market trends
4.4.2 Key growth factors and opportunities
4.4.3 Market size and forecast
4.5 Others
4.5.1 Market size and forecast
CHAPTER 5 GLOBAL ONCOLOGY/CANCER DRUGS MARKET BY CANCER TYPES
5.1 Blood cancer
5.1.1 Epidemiology – prevalence and incidence
5.1.2 Trends in blood cancer treatment
5.1.3 Market size and forecast
5.2 Breast cancer
5.2.1 Epidemiology – prevalence and incidence
5.2.2 Trends in breast cancer treatment
5.2.3 Market size and forecast
5.3 Gastrointestinal cancer
5.3.1 Epidemiology – prevalence and incidence
5.3.2 Trends in treatment of gastrointestinal cancer
5.3.3 Market size and forecast
5.4 Prostate cancer
5.4.1 Epidemiology – prevalence and incidence
5.4.2 Trends in treatment of prostate cancer
5.4.3 Market size and forecast
5.5 Respiratory/lung cancer
5.5.1 Epidemiology – prevalence and incidence
5.5.2 Trends in treatment of lung Cancer
5.5.3 Market size and forecast
5.6 Skin cancer
5.6.1 Epidemiology – prevalence and incidence
5.6.2 Trends in treatment of skin cancer
5.6.3 Market size and forecast
5.7 Other cancers
5.7.1 Trends in treatment of other cancer types
CHAPTER 6 GLOBAL ONCOLOGY/CANCER DRUGS MARKET BY GEOGRAPHY
6.1 North America
6.1.1 Market size and forecast
6.1.2 United States
6.1.2.1 Key market trends
6.1.2.2 Market size and forecast
6.1.3 Canada
6.1.3.1 Key market trends
6.1.3.2 Market size and forecast
6.1.4 Mexico
6.1.4.1 Market size and forecast
6.2 Europe
6.2.1 Key market trends
6.2.2 Market size and forecast
6.2.3 Germany
6.2.3.1 Key market trends
6.2.3.2 Market size and forecast
6.2.4 France
6.2.4.1 Key market trends
6.2.4.2 Market size and forecast
6.2.5 United Kingdom
6.2.5.1 Key market trends
6.2.5.2 Market size and forecast
6.2.6 Others
6.2.6.1 Key market trends
6.2.6.2 Market size and forecast
6.3 Asia Pacific
6.3.1 Key market trends
6.3.1.1 Market size and forecast
6.3.2 India
6.3.2.1 Key market trends
6.3.2.2 Market size and forecast
6.3.3 China
6.3.3.1 Key market trends
6.3.3.2 Market size and forecast
6.3.4 Japan
6.3.4.1 Key market trends
6.3.4.2 Market size and forecast
6.3.5 Australia
6.3.5.1 Key market trends
6.3.5.2 Market size and forecast
6.3.6 Others
6.4 LAMEA
6.4.1 GCC (gulf corporation council)
6.4.1.1 Key Market Trends
6.4.1.2 Market size and forecast
6.4.2 Others
6.4.2.1 Market size and forecast
CHAPTER 7 COMPANY PROFILES
7.1 Amgen Inc.
7.1.1 Company overview
7.1.2 Amgen Inc. snapshot
7.1.3 Financial performance
7.1.4 Operating business segment overview
7.1.5 Key strategies and development
7.1.6 SWOT analysis
7.2 Johnson and Johnson
7.2.1 Company overview
7.2.2 Johnson & Johnson snapshot
7.2.3 Operating business segment overview
7.2.4 Financial performance
7.2.5 Key strategies moves and development
7.2.6 SWOT Analysis
7.3 Roche Diagnostics
7.3.1 Company overview
7.3.2 Roche Diagnostics snapshot
7.3.3 Operating business segment overview
7.3.4 Financial performance
7.3.5 Key strategies moves and development
7.3.6 SWOT analysis
7.4 GlaxoSmithKline PLC
7.4.1 Company overview
7.4.2 GlaxoSmithKline PLC Snapshot
7.4.3 Operating business segment overview
7.4.4 Financial performance
7.4.5 Key strategies move and development
7.4.6 SWOT Analysis of GlaxoSmithKline PLC
7.5 Merck & Company
7.5.1 Company overview
7.5.2 Merck & Company snapshot
7.5.3 Operating business segment overview
7.5.4 Financial performance
7.5.5 Key strategies move and development
7.5.6 SWOT analysis
7.6 Novartis AG
7.6.1 Company overview
7.6.2 Novartis AG snapshot
7.6.3 Operating business segment overview
7.6.4 Financial performance
7.6.5 Key strategies move and development
7.6.6 SWOT analysis
7.7 Pfizer
7.7.1 Company overview
7.7.2 Pfizer snapshot
7.7.3 Operating business segment overview
7.7.4 Financial performance
7.7.5 Key strategies move and development
7.7.6 SWOT analysis
7.8 Sanofi
7.8.1 Company overview
7.8.2 Sanofi snapshots
7.8.3 Operating business segment overview
7.8.4 Financial performance
7.8.5 Key strategies move and development
7.8.6 SWOT analysis
7.9 Eli Lilly and Company
7.9.1 Company overview
7.9.2 Eli Lilly and company snapshots
7.9.3 Operating business segment overview
7.9.4 Financial performance
7.9.5 Key strategies move and development
7.9.6 SWOT analysis
7.10 Celgene Corporation
7.10.1 Company overview
7.10.2 Celgene corporation snapshots
7.10.3 Operating business segment overview
7.10.4 Financial performance
7.10.5 Key strategies move and development
7.10.6 SWOT analysis”
“TABLE 1 MODERATE GROWTH SCENARIO OF ONCOLOGY/ CANCER DRUGS MARKET BY GEOGRAPHY, 2020 – 2025, ($MILLION)
TABLE 2 RAPID GROWTH SCENARIO OF ONCOLOGY/ CANCER DRUGS MARKET BY GEOGRAPHY, 2020 – 2025, ($MILLION)
TABLE 3 DIMINISHING GROWTH SCENARIO OF ONCOLOGY/ CANCER DRUGS MARKET BY GEOGRAPHY, 2020 – 2025, ($MILLION)
TABLE 4 APPLICABLE STANDARDS FOR THE UNITED STATES ANTICANCER DRUG DEVELOPMENT PROCESS
TABLE 5 INTERNATIONAL DISEASE CLASSIFICATION CODES AND DESCRIPTION OF CANCER DIAGNOSES
TABLE 6 CLINICAL LABORATORY FEE SCHEDULE (CLFS) REIMBURSEMENT CODES
TABLE 7 CLINICAL TRIALS FOR ONCOLOGY DRUGS
TABLE 8 WORLDWIDE ESTIMATED INCIDENCE AND PREVALENCE OF ALL CANCER TYPES, (EXCLUDING NON-MELANOMA SKIN CANCER) (2012)
TABLE 9 LIST OF BIOLOGICAL AND TARGETED DRUGS WITH THEIR REVENUE IN 2013 ($MILLION)
TABLE 10 LIST OF KEY PRODUCTS WITH THEIR PATENT EXPIRY DATES
TABLE 11 LIST OF COLLABORATIONS AND ACQUISITIONS FOR DEVELOPMENT OF ANTI-CANCER DRUGS
TABLE 12 GLOBAL ONCOLOGY/CANCER DRUGS MARKET BY THERAPEUTIC MODALITIES, 2013 – 2020 ($MILLION)
TABLE 13 GLOBAL CHEMOTHERAPY DRUGS MARKET BY GEOGRAPHY, 2013 – 2020 ($MILLION)
TABLE 14 GLOBAL TARGETED THERAPY DRUGS MARKET BY GEOGRAPHY, 2013 – 2020 ($MILLION)
TABLE 15 CANCER IMMUNOTHERAPEUTICS AND THEIR CUMULATIVE PRICES
TABLE 16 GLOBAL IMMUNOTHERAPY DRUGS MARKET BY GEOGRAPHY, 2013 – 2020 ($MILLION)
TABLE 17 GLOBAL HORMONAL THERAPY DRUGS MARKET BY GEOGRAPHY, 2013 – 2020 ($MILLION)
TABLE 18 GLOBAL OTHER THERAPY DRUGS MARKET BY GEOGRAPHY, 2013 – 2020 ($MILLION)
TABLE 19 GLOBAL ONCOLOGY/CANCER DRUGS MARKET BY CANCER TYPES, 2013 – 2020 ($MILLION)
TABLE 20 INCIDENCE AND PREVALENCE OF BLOOD CANCER TYPES IN UNITED STATES
TABLE 21 USFDA APPROVED DRUGS FOR THE TREATMENT OF BLOOD CANCERS
TABLE 22 GLOBAL BLOOD CANCER DRUGS MARKET BY GEOGRAPHY, 2013 – 2020 ($MILLION)
TABLE 23 WORLDWIDE INCIDENCE AND PREVALENCE OF BREAST CANCER (2012)
TABLE 24 GLOBAL BREAST CANCER DRUGS MARKET BY GEOGRAPHY, 2013 – 2020 ($MILLION)
TABLE 25 WORLDWIDE INCIDENCE AND PREVALENCE OF GASTROINTESTINAL CANCER (2012)
TABLE 26 GLOBAL GASTROINTESTINAL CANCER DRUGS MARKET BY GEOGRAPHY, 2013 – 2020 ($MILLION)
TABLE 27 WORLDWIDE INCIDENCE AND PREVALENCE OF PROSTATE CANCER (2012)
TABLE 28 DRUGS USED IN PROSTATE CANCER AND THEIR REVENUE (2013)
TABLE 29 GLOBAL PROSTATE CANCER DRUGS MARKET BY GEOGRAPHY, 2013 – 2020 ($MILLION)
TABLE 30 WORLDWIDE INCIDENCE AND PREVALENCE OF LUNG CANCER (2012)
TABLE 31 LIST OF NEW THERAPEUTIC AGENTS FOR LUNG CANCER TREATMENT
TABLE 32 GLOBAL RESPIRATORY/LUNG CANCER DRUGS MARKET BY GEOGRAPHY, 2013 – 2020 ($MILLION)
TABLE 33 GLOBAL SKIN CANCER DRUGS MARKET BY GEOGRAPHY, 2013 – 2020 ($MILLION)
TABLE 34 WORLDWIDE INCIDENCE AND PREVALENCE OF CERVICAL CANCER (2012)
TABLE 35 GLOBAL OTHER CANCER DRUGS MARKET BY GEOGRAPHY, 2013 – 2020 ($MILLION)
TABLE 36 GLOBAL ONCOLOGY/CANCER DRUGS MARKET BY GEOGRAPHY, 2013 – 2020 ($MILLION)
TABLE 37 NORTH AMERICA ONCOLOGY/CANCER DRUGS MARKET BY GEOGRAPHY, 2013 – 2020 ($MILLION)
TABLE 38 COSTS PER THERAPY OF THE COMMON CANCER DRUGS IN THE UNITED STATES:
TABLE 39 UNITED STATES ONCLOGY/CANCER DRUGS MARKET BY THERAPEUTIC MODALITIES, 2013 – 2020 ($MILLION)
TABLE 40 CANADA ONCLOGY/CANCER DRUGS MARKET BY THERAPEUTIC MODALITIES, 2013 – 2020 ($MILLION)
TABLE 41 MEXICO ONCLOGY/CANCER DRUGS MARKET BY THERAPEUTIC MODALITIES, 2013 – 2020 ($MILLION)
TABLE 42 NEW ANTICANCER DRUGS APPROVED BY E MA 2013
TABLE 43 EUROPE ONCLOGY/CANCER DRUGS MARKET BY COUNTRIES, 2013 – 2020 ($MILLION)
TABLE 44 GERMANY ONCLOGY/CANCER DRUGS MARKET BY THERAPEUTIC MODALITIES, 2013 – 2020 ($MILLION)
TABLE 45 FRANCE ONCLOGY/CANCER DRUGS MARKET BY THERAPEUTIC MODALITIES, 2013 – 2020 ($MILLION)
TABLE 46 UNITED KINGDOM ONCLOGY/CANCER DRUGS MARKET BY THERAPEUTIC MODALITIES, 2013 – 2020 ($MILLION)
TABLE 47 OTHERS ONCLOGY/CANCER DRUGS MARKET BY THERAPEUTIC MODALITIES, 2013 – 2020 ($MILLION)
TABLE 48 ASIA PACIFIC ONCLOGY/CANCER DRUGS MARKET BY COUNTRIES, 2013 – 2020 ($MILLION)
TABLE 49 INDIA ONCLOGY/CANCER DRUGS MARKET BY THERAPEUTIC MODALITIES, 2013 – 2020 ($MILLION)
TABLE 50 CHINA ONCLOGY/CANCER DRUGS MARKET BY THERAPEUTIC MODALITIES, 2013 – 2020 ($MILLION)
TABLE 51 JAPAN ONCLOGY/CANCER DRUGS MARKET BY THERAPEUTIC MODALITIES, 2013 – 2020 ($MILLION)
TABLE 52 AUSTRALIA ONCLOGY/CANCER DRUGS MARKET BY THERAPEUTIC MODALITIES, 2013 – 2020 ($MILLION)
TABLE 53 OTHERS ONCLOGY/CANCER DRUGS MARKET BY THERAPEUTIC MODALITIES, 2013 – 2020 ($MILLION)
TABLE 54 LAMEA ONCLOGY/CANCER DRUGS MARKET BY COUNTRIES, 2013 – 2020 ($MILLION)
TABLE 55 GCC ONCLOGY/CANCER DRUGS MARKET BY COUNTRIES, 2013 – 2020 ($MILLION)
TABLE 56 LATIN AMERICAN/ AFRICAN COUNTRIES AND THEIR PRICING POLICIES FOR CANCER THERAPIES
TABLE 57 OTHERS ONCLOGY/CANCER DRUGS MARKET BY THERAPEUTIC MODALITIES, 2013 – 2020 ($MILLION)
TABLE 58 AMGEN INC. SNAPSHOT
TABLE 59 JOHNSON & JOHNSON SNAPSHOT
TABLE 60 JOHNSON AND JOHNSON OPERATING SEGEMENTS
TABLE 61 ROCHE DIAGNOSTICS SNAPSHOT
TABLE 62 ROCHE DIAGNOSTICS OPERATING SEGEMENTS
TABLE 63 GLAXOSMITHKLINE PLC SNAPSHOT
TABLE 64 GLAXOSMITHKLINE PLC OPERATING SEGEMENTS
TABLE 65 MERCK & COMPANY SNAPSHOT
TABLE 66 MERCK & CO. OPERATING SEGEMENTS
TABLE 67 NOVARTIS AG SNAPSHOT
TABLE 68 NOVARTIS AG OPERATING SEGEMENTS
TABLE 69 PFIZER SNAPSHOT
TABLE 70 PFIZER OPERATING SEGEMENTS
TABLE 71 SANOFI SNAPSHOTS
TABLE 72 SANOFI OPERATING SEGEMENTS
TABLE 73 ELI LILLY AND COMPANY SNAPSHOTS
TABLE 74 ELI LILLY AND COMPANY OPERATING SEGEMENTS
TABLE 75 CELGENE CORPORATION SNAPSHOTS”
“FIG. 1 IMPACT ANALYSIS OF GLOBAL ONCOLOGY DRUGS MARKET IN MODERATE GROWTH SCENARIO
FIG. 2 IMPACT ANALYSIS OF GLOBAL ONCOLOGY DRUGS MARKET IN RAPID GROWTH SCENARIO
FIG. 3 IMPACT ANALYSIS OF GLOBAL ONCOLOGY DRUGS MARKET IN DIMINISHING GROWTH SCENARIO
FIG. 4 TOP FACTORS IMPACTING ONCOLOGY DRUGS MARKET (2014-2020)
FIG. 5 TOP INVESTMENT POCKETS OF ONCOLOGY/CANCER DRUGS MARKET (2013)
FIG. 6 TOP WINNING STRATEGIES FOR GLOBAL ONCOLOGY DRUG MARKET (2011-2013)
FIG. 7 TOP WINNING STRATEGIRS BY SUBTYPE
FIG. 8 PORTERS FIVE FORCES ANALYSIS OF ONCOLOGY DRUGS MARKET
FIG. 9 VALUE CHAIN ANALYSIS OF GLOBAL CANCER DRUGS MARKET
FIG. 10 PATENT ANALYSIS BY TYPE OF PATENTS (2011-2015)
FIG. 11 PATENT ANALYSIS BY GEOGRAPHY (2011-2015)
FIG. 12 MARKET SHARE ANALYSIS OF GLOBAL ONCOLOGY DRUG MARKET (2013)
FIG. 13 PERCENTAGE (%) OF ALL NEW CANCERS CASES DIAGNOSED IN 2012
FIG. 14 AMGEN INC. REVENUE BY GEOGRAPHY (2013)
FIG. 15 AMGEN INC. REVENUE BY PRODUCT PORTFOLIO (2013)
FIG. 16 SWOT ANALYSIS OF AMGEN INC.
FIG. 17 FINANCIAL REVENUE OF JOHNSON & JOHNSON BY GEOGRAPHY (2013)
FIG. 18 FINANCIAL REVENUE OF JOHNSON & JOHNSON BY BUSINESS UNITS (2013)
FIG. 19 SWOT ANALYSIS OF JOHNSON & JOHNSON
FIG. 20 FINANCIAL REVENUE OF ROCHE DIAGNOSTICS BY GEOGRAPHY (2013)
FIG. 21 ROCHE DIAGNOSTICS BY BUSINESS UNITS (2013)
FIG. 22 SWOT ANALYSIS OF ROCHE DIAGNOSTICS
FIG. 23 GLAXOSMITHKLINE PLC REVENUE BY GEOGRAPHY (2013)
FIG. 24 GLAXOSMITHKLINE PLC REVENUE BY BUSINESS SEGMENTS (2013)
FIG. 25 SWOT ANALYSIS OF GLAXOSMITHKLINE PLC
FIG. 26 MERCK & CO. REVENUE BY GEOGRAPHY (2013)
FIG. 27 MERCK & CO. REVENUE BY BUSINESS UNITS (2013)
FIG. 28 SWOT ANALYSIS OF MERCK & COMPANY
FIG. 29 NOVARTIS AG REVENUE BY GEOGRAPHY (2013)
FIG. 30 NOVARTIS AG REVENUE BY BUSINESS SEGMENTS (2013)
FIG. 31 SWOT ANALYSIS OF NOVARTIS AG
FIG. 32 PFIZER REVENUE BY GEOGRAPHY (2013)
FIG. 33 PFIZER REVENUE BY BUSINESS SEGMENTS (2013)
FIG. 34 SWOT ANALYSIS OF PFIZER
FIG. 35 SANOFI REVENUE BY GEOGRAPHIES (2013)
FIG. 36 SANOFI REVENUE BY BUSINESS SEGMENTS (2013)
FIG. 37 SWOT ANALYSIS OF SANOFI
FIG. 38 ELI LILLY AND COMPANY REVENUE BY GEOGRAPHIES (2013)
FIG. 39 ELI LILLY AND COMPANY REVENUE BY BUSINESS SEGMENTS (2013)
FIG. 40 SWOT ANALYSIS OF ELI LILLY AND COMAPANY
FIG. 41 CELGENE CORPORATION REVENUE BY GEOGRAPHIES (2013)
FIG. 42 CELEGENE CORPORATION REVENUE BY PRODUCT SALES (2013)
FIG. 43 SWOT ANALYSIS OF CELGENE CORPORATION”
